Compare IMMX & BOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMMX | BOT |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 784.8M | 688.4M |
| IPO Year | 2021 | 2025 |
| Metric | IMMX | BOT |
|---|---|---|
| Price | $8.02 | $21.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $24.05 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 368.5K |
| Earning Date | 11-17-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $20.12 |
| 52 Week High | $15.10 | $43.72 |
| Indicator | IMMX | BOT |
|---|---|---|
| Relative Strength Index (RSI) | 43.88 | 41.35 |
| Support Level | $7.96 | $20.41 |
| Resistance Level | $9.04 | $30.93 |
| Average True Range (ATR) | 0.63 | 2.08 |
| MACD | 0.09 | -0.09 |
| Stochastic Oscillator | 49.49 | 31.38 |
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
RoboStrategy Inc is a closed-end, non-diversified management investment company. The Fund's investment objective is to seek long-term capital appreciation, principally through capital gains on equity and equity-linked investments in robotics and embodied AI companies. The Fund focuses on private, venture-capital-backed companies with growth potential, many of which are not yet publicly listed or widely accessible to individual investors.